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SUMMARY
A non-polymorphic antigen associated with the rhoptry organelles of Plasmodium falciparum has been purified by immuno-
affinity chromatography. The antigen, RAP-1 (rhoptry associated protein-1), which is defined by monoclonal antibodies
which inhibit parasite growth in vitro, is a multi-component antigen consisting of four major proteins of 80, 65, 42 and
40 kDa and two minor proteins of 77 and 70 kDa. These proteins were electro-eluted from preparative sodium dodecyl
sulphate polyacrylamide gels and protected Saimiri sciureus monkeys from a lethal blood-stage infection of P. falciparum
malaria. Sera from the protected animals recognized only proteins of the RAP-1 antigen when used to probe a Western
blot of total parasite protein extract, confirming that RAP-1 is responsible for eliciting the protective immune response.
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INTRODUCTION
The ability of some species of new world monkeys to
support the erythrocytic stage of malarial infection
has allowed vaccination studies to be undertaken in
these primates and early experiments showed that
vaccination with merozoites or schizonts from Plas-
modium falciparum protected against a lethal blood-
stage infection (Mitchell et al. 1977; Siddiqui,
1977). Many merozoite and schizont antigens have
since been identified and their genes cloned and
sequenced. However, only two well-defined antigens
have so far been purified to homogeneity and
successfully used to protect monkeys from infection;
the major merozoite surface antigens derived from
the protein PMMSA (Hall et al. 1984; Perrin et al.
1985a; Siddiqui et al. 1987) and a 41 kDa rhoptry
antigen (Perrin et al. 19856). In the case of one
antigen, RESA, recombinant protein derived from a
repeat region of the gene has offered some protection
(Collins et al. 1986). Synthetic peptides have been
used in some vaccination experiments. A synthetic
peptide corresponding to the N-terminus of the
PMMSA derived 83 kDa protein gave good pro-
tection (Cheung et al. 1986) and a mixture of three
peptides corresponding to the N-termini of the
PMMSA derived 83 kDa protein and two proteins of
55 kDa and 35 kDa, which have not been well
characterized, gave almost full protection (Pattaroyo
et al. 1987). These peptides also formed part of a
complex of peptides from a variety of malarial
antigens which showed some promise in a human
vaccine trial (Pattaroyo et al. 1988).
To our knowledge, only PMMSA has been
* Reprint requests to Professor J. G. Scaife.
repeatedly shown to offer a high degree of protection
in this type of experiment (Hall et al. 1984; Perrin
et al. 1985 a; Siddiqui et al. 1987; our unpublished
results). Because of the small number of candidate
antigens for vaccine development which have been
rigorously tested in model animal systems, we have
sought other antigens which may have protective
properties.
One source of such antigens may be the rhoptry
organelles, which are located at the apex of the
merozoite and are intimately involved in erythrocyte
invasion (Aikawa, 1971; Bannister et al. 1986). In
fact, early studies on the rodent malarial parasite
Plasmodium yoelii revealed a rhoptry antigen which
could partially protect mice against malaria (Holder
& Freeman, 1981). We have previously reported two
monoclonal antibodies 2.13 and 7.12, which define
an antigen, RAP-1 (rhoptry associated protein-1)
associated with the rhoptries (Hall et al. 1983). They
both inhibit parasite growth in vitro (I. A. Hope and
J. G. Scaife, unpublished observations) suggesting
that their target antigen could induce protective
immunity in an anti-malarial vaccine. The RAP-1
antigen, which also offers the advantage of being
non-polymorphic (Clark et al. 1987) has recently
been characterized and its gene cloned (Ridley et al.
1990). We report here the purification of this antigen
and assess its ability to protect Saimiri sciureus
monkevs from malarial infection.
MATERIALS AND METHODS
Standard techniques
Indirect immunofluorescence assays were performed
as described previously (Hall et al. 1983). Sodium
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dodecyl sulphate polvacrvlamide gel electrophoresis
(SDS-PAGE), using the method of Laemmli (1970),
together with Western blotting analysis have also
been previously described (Takacs & Staehli, 1987).
P. falciparum in vitro culture was maintained
according to the method of Trager & Jensen (1976),
later modified by Zolg et al. (1982).
Affinity-purification of RAP-1 antigen
Purified mAb 2.13 (Hall et al. 1983) was coupled
to cyanogen bromide-activated Sepharose 4B
(Pharmacia Ltd, Milton Keynes, UK) as recom-
mended by the manufacturer. Cell pellets of bulk
cultures of a P. falciparum isolate, Kl from Thailand
(Thaithong & Beale, 1981) were harvested as pre-
viously described (Goman et al. 1982) and stored at
— 70 °C until required. They were then extracted at
4 °C for 1 h with an extraction buffer (2°0 (w/v))
sodium deoxycholate, 1 °0 (w/v) Nonidet P40,
50 m.M Tris-HCl (pH 8-(;), 5 m\i ethylene-
diaminetetra-acetic acid (EDTA), 5 m.\i l,2-di(2-
aminoethoxy)ethane-iV,iY,Ar',7V'-tetra-acetic acid
(EGTA)) containing 5 mM-iodoacetamide, 0'2 m\i
phenylmethylsulphonyl fluoride (PMSF) and
10/yg/ml each of the protease inhibitors pepstatin,
chymostatin, antipain, leupeptin and soybean trypsin
inhibitor (all from Sigma Chemical Co. Ltd, Poole,
UK). Fresh PMSF was added to 02 m.M and the
extract was centrifuged at 100000 £ for 3 h at 4 °C.
The supernatant fraction had fresh PMSF added to
0'2 m\i and was passed through a 10 ml column of
Sepharose 4B-bound mAb 2.13 equilibrated with
the extraction buffer. The column was then washed
extensively with wash buffer (0'5 °0 (w/v) sodium
deoxycholate, 1 °0 (w/v) Xonidet P40, 50 mM Tris-
HCl, pH 80, 5 m.M EDTA, 5 m.M EGTA) fol-
lowed by at least 5 column volumes of the wash
buffer containing 015 M NaCl and was finally re-
equilibrated in salt-free wash buffer before eluting
with 50 m\i diethylamine in wash buffer at pH 115.
The protein solution was neutralized with solid
glycine and the cocktail of protease inhibitors at
10/<g/ml was added prior to storage at —70 °C.
Monkey immunization experiment
RAP-1 was purified from the Kl strain of P.
falciparum by affinity chromatography followed by
electro-elution of the protein bands from 15 °0
preparative SDS-polyacrylamide gels. Four Saimiri
sciureus monkeys each received, subcutaneously,
25 //g protein in complete Freund's adjuvant on day
1 and 25 //g protein in incomplete Freund's adjuvant
on days 24 and 48. Control monkeys received the
adjuvant in phosphate-buffered saline on the same
days. Sera were taken on day 56. On day 60,
monkeys received, intravenously, 3'5 x 10' P. falci-
parum (Uganda Palo Alto strain) infected erythro-
Fig. 1. Monoclonal antibody 2.13 punctate
immunofluorescence pattern obtained with the schizont
stage of a Plasmodiutn falciparum-infected erythrocyte.
cytes from a donor monkey. Parasitaemias were
determined by light microscopy of blood smears
stained with Giemsa.
RESULTS
Localization of the antigen RAP-1 to the rhoptry
organelles of the merozoite is shown in Fig. 1. The
punctate fluorescence pattern produced by mAb
2.13 defines rhoptry organelles of parasites at the
late schizont stage of the erythrocytic cycle. Each
parasite within the schizont contains a pair of rhoptry
organelles.
The RAP-1 antigen was purified from extracts of
cultured parasites by affinity chromatography using
mAb 2.13. It consists of four major bands (p80, p65,
p42 and p40) with Mr = 80, 65, 42 and 40 kDa and
two minor bands, Mr = 11 and 70 kDa which varied
in intensity depending on the preparation (Fig. 2).
The high yield of p80 with respect to p70 was heavily
dependent on the addition of protease inhibitors
during extraction, purification and storage of the
antigen, suggesting that p70 is a degradation product
of p80.
The ability of human immune sera to recognize
RAP-1 was tested (Fig. 3). The components p80,
p77, p70, p65 and p40 were all well recognized by
the sera; however, the signal for p42, though present,
was very weak and is not visible in the figure.
Interestingly, p80 showed much stronger immune
recognition than any of the other bands, suggesting
that it contains an immunodominant epitope lacking
in the other RAP-1 components.
The protein bands observed by Coomassie stain-
ing in Fig. 2 were further purified by electro-elution
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Fig. 2. Immuno-affinity purified rhoptry antigen RAP-1
was subjected to SDS-PAGE in the presence of 2-
mercaptoethanol and stained with Coomassie Blue. The
major fractions eluted from an immuno-affinity column
are shown and the sizes of the major bands are
indicated.
1 2
Fig. 3. Recognition of RAP-1 by human immune sera.
Ten samples of Nigerian human immune sera were
pooled and used to probe a Western blot of total
Plasmodium falciparum protein (lane 1) and affinity-
purified RAP-1 (lane 2).
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Fig. 4. Effect of inoculation with RAP-1 on parasitaemia in Saimiri monkeys. Control monkeys are
represented by dotted lines and experimental animals by full lines. Positions are marked to indicate when drug
treatment was administered (T) or death occurred ( + ).
from preparative gels and used to inoculate Saimiri
monkeys. Four animals were treated with the antigen
while four control animals were injected with saline
(Fig. 4). All eight animals were challenged with
blood-stage parasites (Fig. 4). One of the four
experimental monkeys died prematurely with a
ruptured spleen at a parasitaemia significantly lower
than is normally tolerated in these animals. This
monkey produced the lowest titre of antibody by
indirect immunofluorescence. The other three re-
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band is likewise frequently observed in total malarial
protein extract (lane 1) even though it is of low
abundance in affinity-purified RAP-1 as a result of
using protease inhibitors during the extraction and
purification of antigen (lane 2) (see also Fig. 2).
Importantly, no proteins were recognized by the
monkey sera other than those associated with the
RAP-1 antigen. This confirms the purity of the
immunizing antigen and strongly suggests that there
are no cross-reactive epitopes on other malarial
antigens. We conclude that the RAP-1 antigen elicits
an immune response in Saimiri monkeys which
confers protection against falciparum malaria.
- 20
1 2
Fig. 5. Recognition of RAP-1 by monkey antisera. Sera
taken from the experimental monkeys prior to parasite
challenge were pooled and used to probe a Western blot
of total Plasmodium falciparum protein (lane 1) and
affinity-purified RAP-1 (lane 2).
covered completely after developing relatively low
parasitaemias. By contrast, all of the control animals
showed a rapid rise in parasitaemia to 20 °0 by days
8-12 and were cured by chloroquine and Fansidar
treatment. No correlation was observed between
antibody titre and peak parasitaemia in the three
protected animals.
Sera taken from the animals after immunization
and four days prior to parasite challenge, were
assayed for reactivity against RAP-1 and for re-
activity against total parasite protein (Fig. 5). The
sera, which stained rhoptries in indirect immuno-
fluorescence (not shown), recognized purified RAP-
1 in Western blots (lane 2) and detected only
components of the RAP-1 antigen when used to
probe a Western blot of total malarial protein extract
(lane 1). The sera of the four control animals gave
negative results in these tests.
The protein bands in the total protein extract
recognized by the monkey sera in lane 1 correspond
to the bands at 80, 70, 65 and 42 kDa observed in
Fig. 2. We are satisfied that the lower band observed
in Fig. 5 corresponds to p42 as co-migratory signals
have been observed using rabbit antisera raised
specifically against this protein. The protein detected
above p80 at 83 kDa is frequently observed when
blotting total malarial protein extract with both
monoclonal and polyclonal antibodies against RAP-
1 and most likely corresponds to a newly synthesized
precursor protein prior to cleavage of its N-terminal
signal sequence (Ridley et al. 1990). The 70 kDa
DISCUSSION
In this report, we show that the non-polymorphic
rhoptry antigen RAP-1 (Clark et al. 1987) can be
extracted from P. falciparum and can protect Saimiri
monkeys against a lethal infection of falciparum
malaria. It effectively inhibits early multiplication of
the pathogen and permits complete recovery without
further intervention. The sera from the immune
animals recognized only RAP-1 antigen proteins
when used to probe a Western blot of total parasite
protein, confirming that the antigen is responsible
for generating this protection. Furthermore, in
keeping with the antigen's non-polymorphic nature,
the response is not strain limited. The immunizing
antigen, purified from a Thai isolate, Kl , protected
against an isolate of East African origin, Palo Alto
Uganda.
It is not possible at this stage to specify how
humoral and cellular mechanisms participate in the
protection of the monkeys. However, some com-
ments on the immunogenicity of this antigen are
possible.
The RAP-1 antigen is obviously complex, con-
sisting of up to six protein species. The recognition
by monoclonal antibodies of all the higher molecular
weight proteins (p80, p77, p70 and p65) and pulse-
chase data (Clark et al. 1987) has led to the conclusion
that these proteins are all derived from the same
precursor protein (Ridley et al. 1990). In addition,
evidence has also been presented that p42 and p40
may be derived from these higher molecular weight
proteins (Ridley et al. 1990). In the light of these
observations it is interesting to note that the 80 kDa
protein is much more strongly recognized by human
immune sera than the other proteins, suggesting that
a strong immunogenic determinant is present on the
80 kDa protein which is lacking on the other
proteins. In contrast, the 42 kDa component appears
to be poorly immunogenic in man, though the
denatured protein was immunogenic in monkeys.
It should be noted that sera from the experimental
animals recognized a recombinant fusion peptide
derived from the merozoite surface antigen,
PMMSA (Gentz et al. 1988) (not shown). However,
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the sera did not recognize parasite PMMSA or its
products in a Western blot (Fig. 5), nor did they give
the immunofluorescence pattern characteristic of
this antigen (not shown). Perhaps the epitopes
recognized in the fusion peptide (made in Escherichia
coli) are special to this construct.
It needs to be stressed that RAP-1 is different
from another antigen of similar size and subunit
composition, denned by a mAb Hb31cl3, previously
used in monkey immunization experiments (Perrin
et al. 19856). Antibodies raised against the two
antigens do not cross-react (R. Ridley and U. Certa,
unpublished observations). In addition, the 80 kDa
component of the antigen defined by mAb Hb31cl 3
has been identified as a serine protease (Braun-
Breton, Rosenberry & Pereira da Silva, 1988). The
gene sequence encoding RAP-1 has been cloned and
sequenced and does not contain any of the motifs
characteristic of serine proteases (Ridley et al. 1990).
In summary, a non-polymorphic rhoptry antigen,
RAP-1, has been purified from P. falciparum
malarial extracts using immuno-affinity chromato-
graphy and electro-elution from polyacrylamide gels.
This antigen was successfully used to protect Saimiri
monkeys from a lethal infection of P. falciparum
malaria. Further assessment of the antigen's value as
a vaccine requires monkey immunization experi-
ments using recombinant protein material derived
from the gene sequence of RAP-1. Attempts to
express the gene in bacteria are currently in progress.
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